Rounbehler RJ, et al. - Researchers assessed whether the tumor suppressor tristetraprolin (TTP, ZFP36) has clinical usefulness as a biomarker of aggressive disease in prostate cancer patients after radical prostatectomy (RP). They used an RP cohort of patients treated at Moffitt Cancer Center (MCC) and six publicly available RP datasets with biochemical recurrence (BCR) (total n=1,394) and/or metastatic outcome data (total n=1,222). Based on the findings, TTP has value as a prostate cancer biomarker in predicting which RP patients will have poor outcomes, particularly for low-grade prostate cancer patients. The accuracy of Cancer of the Prostate Risk Assessment postsurgical to predict outcomes in patients treated with RP can be enhanced by taking into account TTP RNA expression.